Lynn Huynh
YOU?
Author Swipe
View article: #3452 Real-world effectiveness of ravulizumab in adults with aHUS who switched to ravulizumab within 3 months of eculizumab treatment (aHUS IMPACT)
#3452 Real-world effectiveness of ravulizumab in adults with aHUS who switched to ravulizumab within 3 months of eculizumab treatment (aHUS IMPACT) Open
Background and Aims Atypical haemolytic uraemic syndrome (aHUS) is a progressive rare disease caused by complement dysregulation that, if untreated, can lead to severe organ damage and death. Ravulizumab, a next-generation terminal complem…
View article: Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib Open
Introduction Sonidegib and vismodegib are Hedgehog pathway inhibitors (HHIs) approved for the treatment of locally advanced basal cell carcinoma (laBCC), as well as metastatic basal cell carcinoma (mBCC) for vismodegib. Few studies have co…
View article: Burden of eosinophilic granulomatosis with polyangiitis by disease phase and steroid-sparing effects of biologics: a real-world retrospective study in Europe
Burden of eosinophilic granulomatosis with polyangiitis by disease phase and steroid-sparing effects of biologics: a real-world retrospective study in Europe Open
Objectives To describe insights into real-world characteristics and clinical outcomes of patients with a history of eosinophilic granulomatosis with polyangiitis (EGPA) across Europe, stratified by disease phase and biologics use. Methods …
View article: High Disease Burden and Oral Corticosteroid Use in Patients with Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis: Country-Level Insights into Real-World Management in Europe
High Disease Burden and Oral Corticosteroid Use in Patients with Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis: Country-Level Insights into Real-World Management in Europe Open
Objectives: To analyze variations in patient characteristics, treatment patterns, clinical manifestations, clinical outcomes (i.e., response, flares and flare-free survival in HES; remission, relapses and relapse-free survival in EGPA; and…
View article: Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenic BRCA variants in high-grade serous ovarian carcinoma
Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenic BRCA variants in high-grade serous ovarian carcinoma Open
Background High-grade serous ovarian carcinoma (HGSOC), an aggressive cancer associated with pathogenic BRCA variants, causes genomic instability and sensitivity to poly (ADP-ribose) polymerase inhibitors. Identifying pathogenic BRCA varia…
View article: Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes
Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes Open
Background Limited data exist on the burden of myeloproliferative, lymphocytic and idiopathic subtypes of hypereosinophilic syndrome (M-HES, L-HES and I-HES) and the characteristics of patients with HES receiving biologic therapies. This a…
View article: Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study Open
This study showed that patients with LR-MDS treated with luspatercept required significantly less HRU than patients treated with ESA. Further research is warranted to evaluate the financial impact of this lower HRU burden.
View article: Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma Open
This study assessed the real-world effectiveness of immunoglobulin replacement therapy (IgRT) for treatment of hypogammaglobulinemia and infections in patients with multiple myeloma (MM). A retrospective study was conducted on adult patien…
View article: Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE
Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE Open
Background In Europe, although multiple biologics have been approved for the treatment of severe asthma (SA), comparative data from real-world settings remain limited. This study compared the real-world effectiveness of dupilumab with that…
View article: Resistance to change in family SMEs: Authentic leadership during succession
Resistance to change in family SMEs: Authentic leadership during succession Open
Resistance to change during the succession phase presents a notable challenge within family SMEs due to entrenched traditions and historical legacies. Consequently, managing resistance to change becomes paramount for facilitating a smooth …
View article: Eosinophilic granulomatosis with polyangiitis: Patient profiles from a large US allergy practice
Eosinophilic granulomatosis with polyangiitis: Patient profiles from a large US allergy practice Open
View article: Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma Open
Patients with r/r LBCL have unfavorable outcomes and need more effective treatment alternatives.
View article: Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study
Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study Open
The US ADVANTAGE real-world study demonstrated a significant reduction in severe asthma exacerbations and SCS prescriptions for patients prescribed dupilumab compared with patients prescribed omalizumab during 12 months of follow-up.
View article: IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence Open
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) can develop hypogammaglobulinemia, a form of secondary immune deficiency (SID), from the disease and treatments. Patients with hypogammaglobulinemia with recur…
View article: Burden of eosinophilic granulomatosis with polyangiitis in Europe
Burden of eosinophilic granulomatosis with polyangiitis in Europe Open
Background and aims Real-world evidence characterising the burden of eosinophilic granulomatosis with polyangiitis (EGPA) in Europe is limited. The aim of this study was to characterise patients in a large European EGPA cohort. Methods Thi…
View article: Real-World Characteristics and Clinical Outcomes of European Patients With Hypereosinophilic Syndrome Receiving Biologics in Europe
Real-World Characteristics and Clinical Outcomes of European Patients With Hypereosinophilic Syndrome Receiving Biologics in Europe Open
View article: Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients with Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients with Relapsed/Refractory Aggressive Large B-Cell Lymphoma Open
View article: Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis Open
Background Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA ® ; OT…
View article: REAL-WORLD BIOLOGICS USE IN EUROPEAN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): CHARACTERISTICS AND OUTCOMES
REAL-WORLD BIOLOGICS USE IN EUROPEAN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): CHARACTERISTICS AND OUTCOMES Open
View article: Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison Open
View article: POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy Open
View article: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy Open
View article: A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation Open
This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006–2021) who failed on two or more tyrosine kinase inhibito…
View article: PATTERNS OF IMMUNOGLOBULIN G TESTING AND INFECTION OUTCOMES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING IMMUNOGLOBULIN REPLACEMENT THERAPY
PATTERNS OF IMMUNOGLOBULIN G TESTING AND INFECTION OUTCOMES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING IMMUNOGLOBULIN REPLACEMENT THERAPY Open
Introduction: Infections lead to mortality in up to 50% of patients (pts) with chronic lymphocytic leukemia (CLL). Immunoglobulin G (IgG) testing detects hypogammaglobulinemia (HGG; <500 mg/dL), a secondary immunodeficiency and risk factor…
View article: (507) Predictors of Postoperative IPP Length: A Multicenter, Multinational Analysis
(507) Predictors of Postoperative IPP Length: A Multicenter, Multinational Analysis Open
Introduction Inflatable penile prosthesis (IPP) placement is associated with high postoperative patient satisfaction. Patients often express concerns about postoperative penile length. There is scant evidence in the literature of clinical …
View article: Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor Open
View article: Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020 Open
Real-world evidence (RWE) has garnered great interest to support registration of new therapies and label expansions by the United States Food and Drug Administration (FDA). Currently, practical insights on the design and analysis of regula…
View article: Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020 Open
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
View article: Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020 Open
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
View article: Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020 Open
Real-world evidence (RWE) has garnered great interest to support registration of new therapies and label expansions by the United States Food and Drug Administration (FDA). Currently, practical insights on the design and analysis of regula…